The SEAS Trial.
The pathobiology of aortic stenosis (AS) now is recognized to have many similiarities to that of atherosclerosis, a disease in which lipid lowering therapy with statin drugs has been successful. Accordingly statins have been used to attempt to retard the progression of AS with variable success. The SEAS trial compared the effects of the combination of simvastatin and ezetimibe to placebo in retarding the progression of aortic stenosis (AS) and was the largest randomized trial of such therapies. One thousand eight hundred seventy three patients with moderate AS were included. The group receiving the drugs had a large reduction in LDL cholesterol and a reduction in coronary events. However drug therapy had no effect on the progression of AS. Conclusion. While AS has many similarities to atherosclerosis, lipid lowering therapy does not affect progression of moderate to severe AS.
Carabello
Blase A
BA
Veterans Affairs Medical Center, Houston, TX 77030, USA. blaseanthony.carabello@med.va.gov
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001024:Aortic Valve Stenosis / Q000188:drug therapy / Q000473:pathology*; D001384:Azetidines / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000187:drug effects; D003324:Coronary Artery Disease / Q000188:drug therapy*; D018450:Disease Progression; D000069438:Ezetimibe; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D019821:Simvastatin / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D001384:Azetidines; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019821:Simvastatin; D000069438:Ezetimibe